Marisa Wexler, MS,  senior science writer—

Smiths Medical has launched a medical device designed to help people with chronic obstructive pulmonary disease (COPD) and other respiratory diseases to clear secretions from their lungs and breathe better. “The introduction of the acapella choice blue therapy system enhances the quality of life for those living with…

Lannett is seeking the approval of a generic form of Advair Diskus (fluticasone-salmeterol powder) in the U.S. Such an approval would be expected to provide a less-expensive alternative to the inhalation treatment that generated about $3 billion in total U.S. sales for the 12 months ending in February 2021,…

Weight loss and a low body mass index (BMI) are associated with worse mortality outcomes among men with chronic obstructive pulmonary disease (COPD) in Japan, according to a new study. The study, “Low BMI and weight loss aggravate COPD mortality in men, findings from a large…

The Scottish Medicines Consortium (SMC) has approved AstraZeneca‘s triple combination therapy Trixeo Aerosphere as a maintenance treatment for chronic obstructive pulmonary disease (COPD). The approval specifically covers adults with moderate to severe disease who are not adequately treated by a combination of an inhaled corticosteroid (ICS) and a…

The U.S. Food and Drug Administration (FDA) has granted Organicell Regenerative Medicine permission to begin a clinical trial testing the company’s lead product, Zofin, in people with chronic obstructive pulmonary disease (COPD). The approved trial design will be a double-blinded, placebo-controlled, phase 1/2 trial to assess the…

In people with chronic obstructive pulmonary disease (COPD) who experience acute exacerbations, the use of amoxicillin alone is associated with better outcomes than treatment with amoxicillin in combination with clavulanic acid, another antibiotic, a Danish study shows. The study, “Antibiotic treatment in acute exacerbation of COPD:…

Inhibiting a protein called lymphotoxin beta receptor (LTβR) could be an effective therapeutic strategy for chronic obstructive pulmonary disease (COPD), new research suggests. The findings were published in Nature, in the study “Inhibition of LTβR signalling activates WNT-induced regeneration in lung.” COPD is characterized by the…

Health Care Service Corporation (HCSC) has issued a positive coverage policy for Pulmonx’s Zephyr Endobronchial Valve for treating severe emphysema, a form of chronic obstructive pulmonary disease (COPD). HCSC is the largest customer-owned health insurer in the U.S., and the fifth largest insurer…

The U.S. Food and Drug Administration has granted clearance to PulmoScan, a device developed by Cognita Labs that will facilitate at-home testing of lung function. The device could be useful in providing care to people with respiratory conditions such as asthma and chronic obstructive pulmonary disease…

The first participant has been treated in a clinical trial testing CSA Medical’s RejuvenAir System as a potential treatment for people with moderate to severe chronic obstructive pulmonary disease (COPD) with chronic bronchitis. The participant was treated at Temple University Hospital. At present, the multicenter international…